Treatment of hepatitis C-related kidney disease.
Fabrizi F, Martin P, Cacoub P, Messa P, Donato FM.
Expert Opin Pharmacother. 2015;16(12):1815-27. doi: 10.1517/14656566.2015.1066333. Epub 2015 Jul 10.
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.
Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A.
World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949.
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, Piluso A, Caini P, Ranieri J, Monti M, Laffi G, Zignego AL.
Dig Liver Dis. 2014 Sep;46(9):833-7. doi: 10.1016/j.dld.2014.05.017. Epub 2014 Jun 19.
[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].
Vince A, Duvnjak M, Kurelac I.
Acta Med Croatica. 2013 Oct;67(4):329-38.
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
Tovo CV, de Mattos AA, de Almeida PR.
World J Gastroenterol. 2014 Mar 21;20(11):2867-75. doi: 10.3748/wjg.v20.i11.2867.
Management of HCV patients with cirrhosis with direct acting antivirals.
Boccaccio V, Bruno S.
Liver Int. 2014 Feb;34 Suppl 1:38-45. doi: 10.1111/liv.12391.
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Akahoshi T, Maehara Y, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.
J Gastroenterol Hepatol. 2014 Sep;29(9):1728-35. doi: 10.1111/jgh.12619.
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP.
Liver Int. 2013 Feb;33 Suppl 1:46-55. doi: 10.1111/liv.12067.
[Resistance to protease inhibitors and efficiency of antiviral therapy in patients with chronic hepatitis C].
Batskikh SN, Karandashova IV, Neverov AD, Chulanov VP.
Ter Arkh. 2016;88(3):62-67. doi: 10.17116/terarkh201688362-67.
[Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice].
Znoyko OO, Klimova EA, Maevskaya MV, Shuldyakov АA, Linkova YN, Morozova MA.
Ter Arkh. 2016;88(11):156-162. doi: 10.17116/terarkh20168811156-162.
